APDN icon

Applied DNA Sciences

5.34 USD
+0.22
4.30%
At close Jul 10, 4:00 PM EDT
After hours
5.33
-0.01
0.19%
1 day
4.30%
5 days
16.09%
1 month
14.35%
3 months
-67.64%
6 months
-96.40%
Year to date
-97.12%
1 year
-98.47%
5 years
-100.00%
10 years
-100.00%
 

About: Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.

Employees: 48

0
Funds holding %
of 7,312 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

62% more capital invested

Capital invested by funds: $266K [Q4 2024] → $432K (+$165K) [Q1 2025]

21.13% more ownership

Funds ownership: 2.51% [Q4 2024] → 23.64% (+21.13%) [Q1 2025]

30% less funds holding

Funds holding: 30 [Q4 2024] → 21 (-9) [Q1 2025]

62% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 13

92% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 13

Research analyst outlook

We haven’t received any recent analyst ratings for APDN.

Financial journalist opinion

Based on 4 articles about APDN published over the past 30 days

Neutral
Accesswire
3 days ago
Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements
STONY BROOK, NY / ACCESS Newswire / July 7, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Company"), a leader in PCR-based DNA technologies, today announced that on July 2, 2025, it received written notice (the "Compliance Notice") from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires that companies listed on the Nasdaq Capital Market maintain a minimum bid price of $1.00 per share, and that the Company is therefore in compliance with the Nasdaq Capital Market's listing requirements. Nasdaq also notified the Company in the Compliance Notice that the hearing before the Nasdaq Hearings Panel previously scheduled to take place on July 15, 2025, has been cancelled, and the Company's securities will continue to be listed and traded on The Nasdaq Capital Market.
Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements
Neutral
Accesswire
1 week ago
Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx
- Conducts 27% Workforce Reduction, Ceases Operations at Applied DNA Clinical Labs, Positions LineaRx for Growth - STONY BROOK, NY / ACCESS Newswire / June 30, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN), a leader in PCR-based DNA technologies, announced a strategic restructuring and realignment of resources to focus exclusively on its synthetic DNA manufacturing business, LineaRx. As part of actions undertaken, the Company implemented a workforce reduction of approximately 27% of headcount and has ceased operations at Applied DNA Clinical Labs (ADCL), a business that provides molecular and genetic testing services, effective June 27, 2025.
Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx
Neutral
Accesswire
3 weeks ago
Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward
President and COO Judy Murrah Appointed New Chairperson of the Board of Directors and CEO STONY BROOK, NY / ACCESS Newswire / June 17, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that Chairperson and Chief Executive Officer Dr. James A. Hayward is retiring from the Company and will step down from the Board of Directors effective June 18, 2025, following a distinguished 20-year term.
Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward
Neutral
Accesswire
3 weeks ago
Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3'25 Financial Results Report in Mid-August
STONY BROOK, NY / ACCESS Newswire / June 16, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will resume a regular quarterly investor call schedule, beginning with the release of its fiscal third quarter 2025 financial results in mid-August 2025. In alignment with this resumption, the Company has cancelled its previously scheduled intra-quarter investor call for June 17, 2025.
Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3'25 Financial Results Report in Mid-August
Neutral
Accesswire
1 month ago
Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025
STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding common stock. The Reverse Stock Split will become effective at 12:01 a.m.
Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025
Neutral
Accesswire
1 month ago
Applied DNA Reports Second Quarter Fiscal 2025 Financial Results
- Therapeutic DNA Production Services Segment (LineaRx) Revenues Up 44% Y/Y, Contributing to a 6% Increase in Total Revenues - - Intra-Quarter Investor Conference Call and Webcast Scheduled for  June 3, 2025, at 4:30 PM ET - STONY BROOK, NY / ACCESS Newswire / May 15, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today reported financial results for its second quarter of fiscal 2025 ended March 31, 2025. The Company's Form 10-Q for its fiscal second quarter can be viewed on the SEC Filings page of its Investor Relations website.
Applied DNA Reports Second Quarter Fiscal 2025 Financial Results
Neutral
Accesswire
1 month ago
Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3
STONY BROOK, NY / ACCESS Newswire / May 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, will release its financial results for the second quarter of fiscal year 2025 (ended on March 31, 2025) after the close of the U.S. equity markets on Thursday, May 15, 2025. The Company's Form 10-Q for the period will be filed concurrently and available on the SEC Filings page of its Investor Relations website.
Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3
Neutral
Accesswire
2 months ago
Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA
- Pivot to U.S.-based Supply Chain for Critical Input Materials Completed - STONY BROOK, NY / ACCESS Newswire / April 21, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that LineaRx, Inc., the Company's majority-owned subsidiary, has completed a long-term initiative to source critical input materials for its LineaDNA™ and LineaIVT™ platforms from U.S.-based suppliers. The initiative, undertaken in response to the 2024 BIOSECURE Act and customer demand for a U.S.-based supply chain, comes as the biopharmaceutical industry increasingly considers reshoring manufacturing operations to the U.S. in response to potential tariff impacts and to ensure a stable supply chain.
Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA
Neutral
Accesswire
3 months ago
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
STONY BROOK, NY / ACCESS Newswire / April 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on April 7, 2025, it received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq"), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). As previously reported, the Company was notified on November 12, 2024, that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Minimum Bid Price Requirement.
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
Neutral
Accesswire
3 months ago
Applied DNA Positions TR8 PGx Testing Service as Pre-Emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement
- Company Revamps Pharmacogenomics Go-To-Market Strategy, Targets Validated PGx Assay Towards Specific Use Cases - STONY BROOK, NY / ACCESS Newswire / April 1, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that Applied DNA Clinical Labs (ADCL), its wholly-owned clinical laboratory subsidiary, is repositioning its TR8™ PGx pharmacogenomics testing service to offer tailored subpanels for indication-specific use cases in addition to full panel testing. The first subpanel under ADCL's new go-to-market strategy is for the pre-emptive testing of patients with genetic variants of the DPYD gene that correlate to potentially reduced or absent DPD enzyme activity necessary to metabolize fluoropyrimidines, specifically capecitabine (branded Xeloda) and fluorouracil (5-FU), two chemotherapy drugs that are widely used as part of the standard of care treatment for patients with certain cancers.
Applied DNA Positions TR8 PGx Testing Service as Pre-Emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement
Charts implemented using Lightweight Charts™